EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials

John Newell-Price, Beverly M K Biller, Maria Fleseriu, Beatrice Gueron iD, Grzegorz Binowski, Anna Paćkowska, Mônica R Gadelha

Clinical Endocrinology · 2026-10 · 105 (4) · 452-463

DOI: 10.1111/cen.70166 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Endocrinology, online erschienen am 01.06.2026. Verfasst von John Newell-Price und 6 weiteren Autor:innen. Beteiligte Einrichtung: The School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Quality of Life, Pituitary ACTH Hypersecretion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evaluate the effects of osilodrostat short‐ and long‐term treatment on health‐related quality of life (HRQoL) in Cushing's disease.

Design

LINC 3 and LINC 4 studies (pooled analysis). Patients 185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI‐II], 15.6; EuroQol Five Dimensions Five Levels [EQ‐­5D‐5L], 0.7).

Measurements

Changes from baseline in CushingQoL, BDI‐­II and EQ‐5D‐5L scores. CushingQoL and EuroQol Five Dimensions Three Levels (EQ‐5D‐3L) scores were assessed in analyses of hypocortisolism‐related adverse events (HAEs).

Results

Mean CushingQoL score improved (all p < 0.001) by +7.72 (Week [W]12), +11.45 (W26; achieving minimal clinically important difference [MCID]) and +15.32 (W72). Mean BDI‐II score improved (all p < 0.001) by −19.0% (W12; achieving MCID) and −41.2% (W72). EQ‐5D‐5L utility score improved over W26–72 ( p < 0.01), reaching the MCID range at W26. All items/domains in the HRQoL questionnaires significantly improved over time ( p < 0.001; ordinal mixed‐effects regression), except one BDI‐II item (past failure) and one EQ‐5D‐5L domain (self‐care). CushingQoL total score improved in patients with mild (mean urinary free cortisol [mUFC] ≤ 2x upper limit of normal [ULN]), moderate (mUFC > 2–5 × ULN) and severe (mUFC > 5 × ULN) hypercortisolism. BDI‐II and EQ‐5D‐5L total scores improved in patients with moderate and severe hypercortisolism. Grade 3 HAEs temporarily reduced CushingQoL and EQ‐5D‐3L scores during event weeks. In the multivariable models, longer treatment duration was associated with CushingQoL improvements; higher mUFC, higher body mass index, and occurrence of HAEs were associated with lower CushingQoL scores.

Conclusions

Osilodrostat improved HRQoL, with clinically meaningful, consistent improvements across HRQoL assessments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifePituitary ACTH HypersecretionHumansFemaleMaleAdultPatient Reported Outcome MeasuresMiddle AgedTreatment OutcomeImidazolesPyridines

Stichwörter der Autor:innen

BDI‐IICushing's diseaseCushingQoLEQ‐5D‐5Lhealth‐related quality of lifeosilodrostatpatient‐reported outcomes

Substanzen

OsilodrostatImidazolesPyridines

Autor:innen und Institutionen

  • The School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
  • Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
  • Recordati Rare Diseases, Puteaux, France.
  • MAHTA Intl Sp. z. o. o., Warsaw, Poland.
  • Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

ORCID-Profile: Beatrice Gueron

Zitieren

APA

Newell-Price, J., Biller, B. M. K., Fleseriu, M., Gueron, B., Binowski, G., Paćkowska, A., & Gadelha, M. R. (2026). Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials. Clinical Endocrinology, 105(4), 452-463. https://doi.org/10.1111/cen.70166

Vancouver

Newell-Price J, Biller BMK, Fleseriu M, Gueron B, Binowski G, Paćkowska A, et al. Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials. Clinical Endocrinology. 2026;105(4):452-463. doi:10.1111/cen.70166

BibTeX
@article{NewellPrice2026,
  author = {Newell-Price, John and Biller, Beverly M K and Fleseriu, Maria and Gueron, Beatrice and Binowski, Grzegorz and Paćkowska, Anna and Gadelha, Mônica R},
  title = {Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials},
  journal = {Clinical Endocrinology},
  year = {2026},
  volume = {105},
  number = {4},
  pages = {452--463},
  doi = {10.1111/cen.70166}
}
Kostenlos starten →